FY2025 Earnings Estimate for ABEO Issued By Zacks Small Cap

Abeona Therapeutics Inc (NASDAQ:ABEO) – Investment analysts at Zacks Small Cap increased their FY2025 earnings estimates for shares of Abeona Therapeutics in a research note issued to investors on Monday, May 19th. Zacks Small Cap analyst D. Bautz now anticipates that the biopharmaceutical company will post earnings per share of ($0.64) for the year, up from their previous forecast of ($0.74). The consensus estimate for Abeona Therapeutics’ current full-year earnings is ($1.16) per share.

Several other brokerages have also issued reports on ABEO. Alliance Global Partners restated a “buy” rating on shares of Abeona Therapeutics in a research note on Thursday, May 15th. Oppenheimer began coverage on shares of Abeona Therapeutics in a research note on Wednesday, March 5th. They issued an “outperform” rating and a $16.00 price objective for the company. HC Wainwright lifted their price objective on shares of Abeona Therapeutics from $15.00 to $20.00 and gave the company a “buy” rating in a research note on Wednesday, April 30th. Wall Street Zen lowered shares of Abeona Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, May 15th. Finally, Stifel Nicolaus reduced their price objective on shares of Abeona Therapeutics from $21.00 to $20.00 and set a “buy” rating for the company in a research note on Friday, May 16th. One investment analyst has rated the stock with a sell rating and five have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $18.50.

Abeona Therapeutics Trading Up 2.0%

Shares of ABEO stock opened at $6.58 on Thursday. The company has a 50 day moving average of $5.27 and a 200-day moving average of $5.56. The company has a quick ratio of 6.12, a current ratio of 6.12 and a debt-to-equity ratio of 0.31. Abeona Therapeutics has a 12-month low of $3.93 and a 12-month high of $7.32. The firm has a market cap of $321.10 million, a P/E ratio of -2.45 and a beta of 1.68.

Abeona Therapeutics (NASDAQ:ABEO) last issued its quarterly earnings results on Thursday, May 15th. The biopharmaceutical company reported ($0.24) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.35) by $0.11.

Insider Activity at Abeona Therapeutics

In other news, CEO Vishwas Seshadri sold 25,000 shares of the business’s stock in a transaction on Monday, March 31st. The shares were sold at an average price of $4.78, for a total transaction of $119,500.00. Following the completion of the transaction, the chief executive officer now directly owns 1,355,322 shares in the company, valued at $6,478,439.16. The trade was a 1.81% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Mark Alvino sold 8,000 shares of the business’s stock in a transaction on Friday, May 16th. The shares were sold at an average price of $5.68, for a total transaction of $45,440.00. Following the transaction, the director now owns 92,435 shares of the company’s stock, valued at $525,030.80. This trade represents a 7.97% decrease in their ownership of the stock. The disclosure for this sale can be found here. 6.90% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the company. Twinbeech Capital LP purchased a new position in shares of Abeona Therapeutics during the 4th quarter valued at $58,000. Squarepoint Ops LLC purchased a new position in shares of Abeona Therapeutics during the 4th quarter valued at $67,000. Cannon Global Investment Management LLC purchased a new position in Abeona Therapeutics in the first quarter worth $67,000. Oxford Asset Management LLP purchased a new position in Abeona Therapeutics in the fourth quarter worth $118,000. Finally, Balyasny Asset Management L.P. purchased a new position in Abeona Therapeutics in the fourth quarter worth $190,000. 80.56% of the stock is currently owned by hedge funds and other institutional investors.

About Abeona Therapeutics

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.